Showing results (161-170 of 208) with videos related to

Sort By:
Pageof 21
Journal of Translational Medicine|September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine|October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant TreatmentClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
Pageof 21